InspireMD Inc (NYSEAMERICAN:NSPR) Short Interest Update

InspireMD Inc (NYSEAMERICAN:NSPR) was the recipient of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 246,100 shares, an increase of 18.7% from the August 15th total of 207,300 shares. Based on an average trading volume of 3,680,000 shares, the short-interest ratio is presently 0.1 days.

An institutional investor recently raised its position in InspireMD stock. Wedbush Securities Inc. raised its stake in shares of InspireMD Inc (NYSEAMERICAN:NSPR) by 211.6% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 120,508 shares of the medical equipment provider’s stock after buying an additional 81,838 shares during the period. Wedbush Securities Inc. owned about 2.78% of InspireMD worth $56,000 at the end of the most recent quarter.

Separately, Zacks Investment Research downgraded InspireMD from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd.

NSPR stock traded down $0.01 during midday trading on Wednesday, reaching $0.35. 629,168 shares of the company traded hands, compared to its average volume of 2,026,536. InspireMD has a 52-week low of $0.33 and a 52-week high of $4.50.

InspireMD (NYSEAMERICAN:NSPR) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.15. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.20 million.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions.

Featured Story: Why Invest in Dividend Kings

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with's FREE daily email newsletter.

Leave a Reply